Sustained response to combination therapy in a patient with chronic hepatitis C and thrombocytopenia secondary to α-interferon

Journal of Gastroenterology and Hepatology (Australia)

Volumn 15, Issue 5, 2000, Pages 567-569

  Jiménez Sáenz, Manuel ^a   Rojas, MARÍA ^a   Piñar, Angel ^a   Salas, Ernesto ^a   Rebollo, Jaime ^a   Carmona, Isabel ^a   Herrerías Esteban, Juan Manuel ^a   Herrerías Gutiérrez, Juan Manuel ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

Chronic hepatitis C; Combined therapy; Thrombocytopenic purpura

Indexed keywords

ALPHA INTERFERON; IMMUNOGLOBULIN G; RIBAVIRIN;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; AUTOIMMUNITY; CASE REPORT; CHRONIC HEPATITIS; COMBINATION CHEMOTHERAPY; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG EFFECT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; PRIORITY JOURNAL; THROMBOCYTOPENIA; VIRUS HEPATITIS;

EID: 0034119015     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2000.02155.x     Document Type: Article

References (15)

1. 1 Hernandez F, Blanquer A, Linares M, Lopez A, Tarin F, Cervero A. Autoimmune thrombocytopenia associated with hepatitis C virus infection. Acta Haematol. 1998; 99: 217-20.
2. 2 López-Morante AJ, Sáez-Royuela F, Casanova Valero F, Yugero del Moral L, Marin Lorente JL, Ojeda Gimenez C. Immune thrombocytopenia after alpha-interferon therapy in a patient with chronic hepatitis. Am. J. Gastroenterol. 1992; 87: 809-10.
3. 3 Murakami CS, Zeller K, Bodenheimer HC, Lee WM. Idiopathic thrombocytopenic purpura during interferon-alpha 2b treatment for chronic hepatitis. Am. J. Gastroenterol. 1994; 89: 2244-5.
4. 4 Sherestha R, McKinley C, Bilir BM, Everson GT. Possible idiopathic thrombocytopenia purpura associated with natural alpha Interferon therapy for chronic hepatitis C infection. Am. J. Gastroenterol. 1995; 90: 1146-7.
5. 5 Khan HA, Khawaja FI, Mahrous ARS. Life-threatening severe immune thrombocytopenia after alpha-interferon therapy for chronic hepatitis C infection. Am. J. Gastroenterol. 1996; 91: 821-2.
6. 6 Dourakis S, Deutsch M, Hadziyannis SJ. Immune thrombocytopenia and alpha-interferon therapy. J. Hepatol. 1996; 25: 972-5.
7. 7 Soto B, Andreu J, Sánchez-Quijano A et al. To be or not to be: Is that the question in the interferon therapy of chronic hepatitis C? J. Hepatol. 1993; 18 (Suppl.): S173.
8. 8 Peck-Radosavljevic M, Zacherl J, Meng G et al. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver. J. Hepatol. 1997; 27: 127-31.
9. 9 Peck-Radosavljevic M, Wichlas M, Pidlich J et al. Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. Hepatology 1998; 28: 1424-9.
10. 10 Garcia-Buey ML, García-Monzón C, Rodriguez S et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995; 108: 1770-7.
11. 11 Okanoue T, Sakamoto S, Itoh Y et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J. Hepatol. 1996; 25: 283-91.
12. 12 Nagamine T, Ohtuka T, Takehara K, Arai T, Takagi H, Mori M. Thrombocytopenia associated with hepatitis C viral infection. J. Hepatol. 1996; 24: 135-40.
13. 13 Tappero G, Negro F, Farina M, Gallo M, Angeli A, Hadengue A. Safe switch to β-interferon treatment of chronic hepatitis C after α-interferon-induced autoimmune thrombocytopenia. J. Hepatol. 1996; 25: 270.
14. 14 Ning Q, Brown D, Parodo J et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgI2 prothrombinase and preserves Th2 cytokine production but inhibits Th2 cytokine response. J. Immunol. 1998; 160: 3487-93.
15. 15 Jaccard A, Loustaud V, Turlure P, Rogez S, Bordessoule D. Ribavirin and immune thrombocytopenic purpura. Lancet 1998; 351: 1660-1.